The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| DICERNA PHARMACEUTICALS INC | COM | 253031108 | 114,954 | 3,080,237 | SH | SOLE | 3,080,237 | 0 | 0 | ||
| MARINUS PHARMACEUTICALS INC | COM | 56854Q200 | 25,673 | 1,431,058 | SH | SOLE | 1,431,058 | 0 | 0 | ||
| SOLID BIOSCIENCES INC | COM | 83422E105 | 29,024 | 7,929,918 | SH | SOLE | 7,929,918 | 0 | 0 | ||
| APTINYX INC | COM | 03836N103 | 25,164 | 8,891,758 | SH | SOLE | 8,891,758 | 0 | 0 | ||
| SPRINGWORKS THERAPEUTICS INC | COM | 85205L107 | 480,558 | 5,831,307 | SH | SOLE | 5,831,307 | 0 | 0 | ||
| DYNAVAX TECHNOLOGIES CORP | COM | 268158201 | 115,951 | 11,771,708 | SH | SOLE | 11,771,708 | 0 | 0 | ||
| X4 PHARMACEUTICALS INC | COM | 98420X103 | 13,777 | 2,119,540 | SH | SOLE | 2,119,540 | 0 | 0 | ||
| SAVARA INC | COM | 805111101 | 19,758 | 11,622,598 | SH | SOLE | 11,622,598 | 0 | 0 | ||
| ARCUTIS BIOTHERAPEUTICS INC. | COM | 03969K108 | 108,595 | 3,979,292 | SH | SOLE | 3,979,292 | 0 | 0 | ||
| MERSANA THERAPEUTICS INC. | COM | 59045L106 | 50,187 | 3,695,667 | SH | SOLE | 3,695,667 | 0 | 0 | ||
| CRINETICS PHARMACEUTICALS | COM | 22663K107 | 31,662 | 1,679,701 | SH | SOLE | 1,679,701 | 0 | 0 | ||
| AEGLEA BIO THERAPEUTICS INC | COM | 00773J103 | 18,792 | 2,700,000 | SH | SOLE | 2,700,000 | 0 | 0 | ||
| ANNEXON INC | COM | 03589W102 | 72,969 | 3,241,628 | SH | SOLE | 3,241,628 | 0 | 0 | ||
| NURIX THERAPEUTICS INC | COM | 67080M103 | 34,073 | 1,284,314 | SH | SOLE | 1,284,314 | 0 | 0 | ||
| KYMERA THERAPEUTICS INC. | COM | 501575104 | 23,261 | 479,605 | SH | SOLE | 479,605 | 0 | 0 | ||
| RESEARCH ALLIANCE CORP II | COM CL A | 760873109 | 10,140 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 | ||
| NAUTILUS BIOTECHNOLOGY INC. | COM | 63909J108 | 20,200 | 2,000,000 | SH | SOLE | 2,000,000 | 0 | 0 | ||
| BCTG ACQUISITION CORP | COM | 05492W103 | 10,490 | 921,790 | SH | SOLE | 921,790 | 0 | 0 | ||
| SYROS PHARMACEUTICALS INC. | COM | 87184Q107 | 31,528 | 5,785,036 | SH | SOLE | 5,785,036 | 0 | 0 | ||
| ATEA PHARMACEUTICALS, INC. | COM | 04683R106 | 120,624 | 5,615,659 | SH | SOLE | 5,615,659 | 0 | 0 | ||
| C4 THERAPEUTICS, INC. | COM STK | 12529R107 | 62,141 | 1,642,209 | SH | SOLE | 1,642,209 | 0 | 0 | ||
| BCLS ACQUISITION CORP | COM CL A | G0904B105 | 5,133 | 487,500 | SH | SOLE | 487,500 | 0 | 0 | ||
| JIYA ACQUISITION CORP | COM CL A | 47760M102 | 2,982 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| HELIX ACQUISITION CORP | COM CL A | G4444C102 | 2,588 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| FRAZIER LIFESCIENCES ACQU CO | UNIT 12/09/2025 | G3710A121 | 3,015 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| PHARVARIS N.V. | COM | N69605108 | 59,255 | 3,180,601 | SH | SOLE | 3,180,601 | 0 | 0 | ||
| ARYA SCIENCES ACQU CORP IV | CL A | G31659108 | 7,504 | 700,000 | SH | SOLE | 700,000 | 0 | 0 | ||
| PANACEA ACQUISITION CORP II | CL A SHS | G6882C106 | 5,010 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| BLUEBIRD BIO, INC. | COM | 09609G100 | 17,211 | 538,179 | SH | SOLE | 538,179 | 0 | 0 | ||
| OMEGA ALPHA SPAC | CL A | G6749V107 | 3,980 | 400,000 | SH | SOLE | 400,000 | 0 | 0 | ||